Enigma Biomedical Group (EBG) and Invicro, a Konica Minolta Company and a provider of imaging services and software for research and drug development, have collaborated on multiple projects, initially focusing on the enhancement of Invicro’s Amyloid and Tau platforms. EBG will be responsible for providing data from their affiliate companies; Cerveau Technologies, Inc. and Meilleur Technologies, Inc.; novel Tau tracer (MK-6240) and Amyloid tracer (NAV-4694); respectively.
As part of the agreement, both parties will utilize the Amyloid and Tau platforms to provide the pharmaceutical industry access to improved informatics and analytics capabilities together with a more streamlined approach to supporting neurodegenerative disease modifying therapy development.
Lee-Anne Gibbs, president of Enigma Biomedical Group said, “This is an important step in accelerating critical biomarker research projects globally and supporting our pharmaceutical partners efforts to combat neurodegenerative disease. Collaborating with Invicro’s IQ technology platform allows Enigma and our partners Cerveau and Meilleur, to continue to execute the collective strategy of providing biomarkers to industry and academics to accelerate research in the field of Neurodegenerative disease.”
“Working with Enigma to expand Invicro’s novel Amyloid and Tau platforms, we aim to jointly accelerate neuroimaging clinical trials through improved effect size using advanced analytics. We are extremely impressed by the Enigma portfolio and look forward to a great research partnership in the coming years.” stated Dr. Jack Hoppin, co-founder and CEO of Invicro.
“Encoding of advanced neurological domain knowledge into AI algorithms has enabled the exciting development of the Amyloid and Tau platforms” said Dr Roger Gunn, executive vice president, Quantitative Data Sciences, Invicro LLC and one of the inventors of the IQ-Analytics platforms. “We are delighted to be working with Enigma to apply these breakthrough algorithms to their amyloid and tau tracers in order to provide increased value for researchers running clinical trials in neurodegeneration”
“At Enigma, we are focused on providing information and technologies to researchers and clinicians to enable the improvement of brain health” said Rick Hiatt, chief executive officer of Enigma Biomedical Group and President and CEO of Cerveau Technologies, Inc. “We are thrilled by the opportunity to work with Invicro to foster development of this exciting technology. Consistent with our vision, we will make novel imaging biomarkers and supporting informatics available to our pharmaceutical industry and academic partners, providing access to the broader scientific community.”
(Source: Enigma Biomedical Group)
Filed Under: Drug Discovery
